KRAS mutant antigen specific TCR-T cells

KRAS mutant antigen-specific TCR-T cells are an investigational autologous cell therapy consisting of T cells engineered to express a specific T-cell receptor (TCR) designed to recognize neoantigens derived from mutated KRAS proteins, specifically those involving G12D or G12V substitutions. These mutations are highly prevalent in solid tumors such as pancreatic, colorectal, and lung cancers. The therapy functions by identifying the intracellular KRAS mutant peptides presented on the tumor cell surface via specific Human Leukocyte Antigen (HLA) class I molecules. By utilizing the patient's own immune cells modified for high-affinity recognition of these driver mutations, TCR-T therapy aims to induce targeted tumor cell lysis while sparing healthy tissues that lack the specific mutation. Current clinical development, such as in trial NCT05438667, often involves a conditioning lymphodepletion regimen followed by T-cell infusion and subsequent administration of interleukin-2 to support T-cell expansion and persistence.

Other names

KRAS-specific TCR-T cell therapyKRAS-targeted TCR-T cellsAutologous TCR-T cells targeting KRAS mutations